Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harmony Biosciences HoldingsHRMY +1.35%94 Gross Margin % is 75.81% as of Jun. 2026, which is 4% below its 10-year median of 79.17. GuruFocus rates HRMY with a GF Score™ of 94/100 and a GF Value™ of $46.81 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 734 Biotechnology companies, Harmony Biosciences Holdings ranks better than 68.12% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Harmony Biosciences Holdings had a gross margin of 75.81% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Harmony Biosciences Holdings Gross Margin % Related Terms
Harmony Biosciences Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HRMY vs SION, URGN, PVLA: Gross Margin % Comparison
For the Biotechnology subindustry, Harmony Biosciences Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harmony Biosciences Holdings Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Harmony Biosciences Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Harmony Biosciences Holdings (HRMY) has a Gross Margin % of 75.81% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Harmony Biosciences Holdings and its competitors. This is near median its historical median of 79.17. Over the past decade, Harmony Biosciences Holdings' Gross Margin % has ranged from 73.69 to 82.64. According to the industry distribution chart, Harmony Biosciences Holdings ranks #234 out of 734 companies in the Biotechnology industry, placing it in the top 31.9%.
Is Harmony Biosciences Holdings' Gross Margin % too high?
Harmony Biosciences Holdings' current Gross Margin % of 75.81% is near median its 10-year median of 79.17. Over the past 10 years, this metric has ranged from a low of 73.69 to a high of 82.64. The Biotechnology industry median Gross Margin % is 60.91. Harmony Biosciences Holdings' value of 75.81% is 24.5% above this industry median. Based on the distribution chart, Harmony Biosciences Holdings ranks #234 out of 734 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Harmony Biosciences Holdings has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' Gross Margin % compare to SION and URGN?
According to the Biotechnology industry distribution chart, Harmony Biosciences Holdings ranks #234 out of 734 companies for Gross Margin %. This puts Harmony Biosciences Holdings in the upper half of its industry. The industry median Gross Margin % is 60.91. Harmony Biosciences Holdings' value of 75.81% is 24.5% above this benchmark. Historically, Harmony Biosciences Holdings' own Gross Margin % has ranged from 73.69 to 82.64 over the past decade. While the company's 10-year median is 79.17 vs. the industry median of 60.91, Harmony Biosciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harmony Biosciences Holdings's current Gross Margin % of 75.81% is 24.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Harmony Biosciences Holdings and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harmony Biosciences Holdings's current Gross Margin % is 75.81%, which is near median its own 10-year median of 79.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.81, compared to a current price of $38.74 — trading 17.2% below its estimated fair value. The current Gross Margin % is 75.81%, which is near median its 10-year median of 79.17 and 24.5% above the Biotechnology industry median of 60.91. Harmony Biosciences Holdings' overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current Gross Margin % is 75.81% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?
Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued.
The current stock price of $38.74 is trading 17.2% below its estimated GF Value™ of $46.81.
GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.
Key valuation signals for HRMY:
Gross Margin %: 75.81% (near median its 10-year median of 79.17)
GF Value™: $46.81 vs. price of $38.74 (17.2% below fair value)
Industry Position: 24.5% above the Biotechnology median (#234 of 734)
No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
94GF Score
Get the complete analysis for HRMY
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRMY has been successfully added to your 
